Antonio Pato

Effectiveness and Safety of Cladribine in Relapsing-Remitting Multiple Sclerosis in Clinical Practice: A 2-Year Multicenter Retrospective Open-Label Study.

Journal: Annals of Indian Academy of Neurology

Published: October 06, 2025

Rituximab in anti-HMG-CoA reductaseimmune-mediated necrotizing myopathyrefractory to treatment.

Journal: Neurologia

Published: May 27, 2025

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: May 01, 2025

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: May 01, 2025

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Journal: Journal of patient-reported outcomes

Published: June 21, 2024

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Journal: Neurologia

Published: February 22, 2024

Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

Journal: Multiple sclerosis and related disorders

Published: November 23, 2022

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Journal: PloS one

Published: June 14, 2021

Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.

Journal: Epilepsy research

Published: November 18, 2020

LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.

Journal: Epilepsy research

Published: January 19, 2018

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

Journal: Neurologia

Published: June 07, 2017

Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia

Journal: Revista de neurologia

Published: September 24, 2016

Effectiveness and Safety of Cladribine in Relapsing-Remitting Multiple Sclerosis in Clinical Practice: A 2-Year Multicenter Retrospective Open-Label Study.

Effectiveness and Safety of Cladribine in Relapsing-Remitting Multiple Sclerosis in Clinical Practice: A 2-Year Multicenter Retrospective Open-Label Study.

Rituximab in anti-HMG-CoA reductaseimmune-mediated necrotizing myopathyrefractory to treatment.

Rituximab in anti-HMG-CoA reductaseimmune-mediated necrotizing myopathyrefractory to treatment.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Alemtuzumab and autoimmune polyglandular syndrome with type 1 diabetes mellitus.

Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.

Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.

LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.

LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.

Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia

Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

[Translated article] Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.

Alemtuzumab in relapsing-remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years.